Early COVID‐19 treatment with Sotrovimab in high‐risk Beta‐thalassemia: Real‐life case‐series, state of the art and new perspectives
Abstract
Dear Editor, This report aims to provide a clinical demonstration of the safety and effectiveness of sotrovimab, regarding our experience in using this preventative therapy, with realworld data, which are scarce and sometimes conflicting during the different waves of the pandemic. Neutralizing monoclonal antibodies (mAbs) have been shown to reduce COVID19 severity in patients with underlying predisposing conditions. mAbs such as sotrovimab, casirivimab/imdevimab and bamlanivimab/etesevimab are effective at reducing the risk of subsequent hospitalization in COVID19 outpatients and have since received US Food and Drug Administration (FDA) emergencyuse authorization for this indication1,2 (Table 1). Sotrovimab is a pansarbecovirus mAb useful to prevent the progression of COVID19 in highrisk patients. To date, little is known about the efficacy, tolerability and indications of mAbs in thalassaemia patients with COVID19. The prevalence of SARSCoV2 infection among beta (β) thalassaemia seems to be lower than the general population, however, associated comorbidities confer the risk of more severe disease, with a fivefold increase in agestandardized lethality.3,4 Considering the position statement of the Thalassaemia International Federation (TIF), the highest risk group for severe infectious complications, included thalassaemia patients with splenectomy and one or more severe systemic diseases, underlying comorbidities such as diabetes, cardiac, endocrine, hepatic or respiratory…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 51 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.